[ad_1]
One of the main objectives of “regulating the supply of Sars-CoV-2 drugs” is to guarantee an optimal supply of drugs for the population. This also includes reducing doctor-patient contacts during the pandemic corona. Consequently, pharmacies were somewhat easier to deliver prescriptions. In case of unavailability, the pack size, the number of packets or the power may differ. If an active ingredient is not available in any dosage or package size, the pharmacist may also administer a similar active ingredient after consulting the doctor.
Equivalence dose as a guide
When switching a patient to an alternative active ingredient, it is important to know the corresponding equivalent doses. There is enough valid data for some active substances, so AMK has published tables for the conversion. The AMK emphasizes that these tables are only indicative of a possible alternative dose. In individual cases, in addition to the indication, interactions, pharmacokinetics, contraindications and patient-specific factors should also be considered. Pharmacies must use specialized information relevant to this.
Five published tables
The AMK provides equivalency dose tables for the following five groups of active ingredients:
- ACE inhibitors
- Angiotensin II receptor blockers (sartans)
- Inhaled corticosteroids
- Proton pump inhibitors (PPI)
- Triptans
In addition to the equivalent dose of the medicine, the tables also contain information on the recommended starting and maintenance doses in the respective indication. For example, the usual recommended starting dose for treating hypertension with lisinopril is 10 milligrams once a day, and the active ingredient captopril is initially divided into two doses. The best known is the comparison table of angiotensin II receptor blockers (sartans), which the AMK had already provided as a result of the valsartan scandal.
[ad_2]
